TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29547049

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (de novo group)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (prior octreotide group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (de novo group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (prior octreotide group)
Number of subjects: 115
Study: 26909683

Group type: EXPERIMENTAL
Intervention: HNC (Helping the Noncompliant Child)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: NFPP (New Forest Parenting Programme)
Number of subjects: 130
Study: 24338935

Group type: EXPERIMENTAL
Intervention: Spironolactone (titrating dose, 12.5-50 mg once daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Clonidine (titrating dose, 0.1-0.3 mg twice daily)
Number of subjects: 2000
Study: 23198694

Group type: EXPERIMENTAL
Intervention: Chinese diabetes group visit program (12 monthly group visit sessions)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study: 19081412

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher stents (SESs)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare-metal BxVelocity stents (BMSs)
Number of subjects: 200
Study: 17403121

Group type: EXPERIMENTAL
Intervention: rosiglitazone + metformin (8/2000 mg)
Number of subjects: 324

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 324
Study: 15505875

Group type: EXPERIMENTAL
Intervention: Radioisotope occult lesion localization (ROLL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wire localization
Number of subjects: 95
Study: 11136485

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate, 50 mg once daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9693995

Group type: EXPERIMENTAL
Intervention: REM sleep measures in OAD patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: REM sleep measures in DAT patients
Number of subjects: 116

Group type: COMPARATOR
Intervention: REM sleep measures in healthy controls
Number of subjects: 116
Study: 7935635

Group type: EXPERIMENTAL
Intervention: Radioiodinated vasoactive intestinal peptide (VIP) administered as a single intravenous bolus injection (300 pmol [1 microgram])
Number of subjects: 79

Group type: COMPARATOR
Intervention: Somatostatin analogues
Number of subjects: 79
Study: 3588972

Group type: EXPERIMENTAL
Intervention: DHV‐PGE2 ME, 120 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DHV‐PGE2 ME, 30 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inactive vehicle
Number of subjects: 12
Study: 29156056

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 8000 IU/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 27475753

Group type: EXPERIMENTAL
Intervention: Pregabalin (75-450 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 23617693

Group type: EXPERIMENTAL
Intervention: Isotretinoin 5 mg/day for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotretinoin 5 mg/day after 16 weeks of placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isotretinoin 5 mg/day for 32 weeks
Number of subjects: 0
Study: 20220604

Group type: EXPERIMENTAL
Intervention: TIP intervention (psychosocial intervention targeting psychological barriers to depression care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 17655947

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin (low dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (high dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17063827

Group type: COMPARATOR
Intervention: Microwave energy in the frequency range of 250 approximately 550MHz irradiated on an acupuncture point.
Number of subjects: 150
Study: 12462550

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy (HRT)
Number of subjects: 17835

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 17835

Group type: COMPARATOR
Intervention: Never use of PMH
Number of subjects: 17835
Study: 11396038

Group type: EXPERIMENTAL
Intervention: School-based dental health education program for 6 months
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: School-based dental health education program for 12 months
Number of subjects: 2678

Group type: COMPARATOR
Intervention: Early intervention group (6 months)
Number of subjects: 2678

Group type: COMPARATOR
Intervention: Early intervention group (12 months)
Number of subjects: 2678
Study: 7740333

Group type: EXPERIMENTAL
Intervention: IV vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV vinorelbine (first-line therapy)
Number of subjects: 0
Study: 2201742

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg every 12 h for 5 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: Ampicillin, 500 mg every 6 h for 5 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 121
Study: 7026260

Group type: EXPERIMENTAL
Intervention: Sublingual isoxsuprine 20 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral isoxsuprine 20 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31092668

Group type: EXPERIMENTAL
Intervention: Guided web‐based transdiagnostic individually tailored intervention (7 online sessions over 4 to 7 weeks, with a booster session 4 weeks after completion)
Number of subjects: 0
Study: 28526720

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.2 mg/m2
Number of subjects: 66
Study: 26484510

Group type: EXPERIMENTAL
Intervention: Real tDCS during RT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS during RT
Number of subjects: 22
Study: 23722126

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel applied twice a day for one week
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gel applied twice a day for one week
Number of subjects: 88
Study: 21321426

Group type: EXPERIMENTAL
Intervention: 200 mg of Panax ginseng (PG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 19761681

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (added if target blood pressure not achieved)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups (ACEi and ARB combined)
Number of subjects: 44
Study: 17762803

Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham neck massage
Number of subjects: 120

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 120
Study: 15177823

Group type: EXPERIMENTAL
Intervention: Unilateral forced nostril breathing (UFNB) through the left nostril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral forced nostril breathing (UFNB) through the right nostril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congruent UFNB (breathing through dominant nostril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent UFNB (breathing through non-dominant nostril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 11273588

Group type: EXPERIMENTAL
Intervention: LVSFU2 (bimonthly regimen)
Number of subjects: 905

Group type: COMPARATOR
Intervention: FUFOL (monthly regimen)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: LVSFU2
Number of subjects: 905
Study: 10896408

Group type: EXPERIMENTAL
Intervention: Halofantrine (1500 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chloroquine (1500 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halofantrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 20
Study: 8551452

Group type: EXPERIMENTAL
Intervention: High-viscosity viscoelastic used for intraocular lens (IOL) implantation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low-viscosity viscoelastic used for intraocular lens (IOL) implantation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 2
Study: 2229459

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 354330

Group type: EXPERIMENTAL
Intervention: Sustained release amitriptyline (Saroten Retard)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional amitriptyline tablets (Saroten)
Number of subjects: 24
Study: 29023998

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including behavioral lifestyle modification program and pranayama sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0
Study: 26840887

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate with a higher content of bioactive collagen peptides (H-CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collagen hydrolysate with a lower content of bioactive collagen peptides (L-CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24770406

Group type: EXPERIMENTAL
Intervention: Non-skin thinning technique (test group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Flap technique (control group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dermatome technique (control group)
Number of subjects: 36
Study: 23194490

Group type: EXPERIMENTAL
Intervention: Exercise with testosterone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exercise with placebo
Number of subjects: 41
Study: 20020312

Group type: EXPERIMENTAL
Intervention: Group A (weak intervention)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group B (strong intervention)
Number of subjects: 49
Study: 18824996

Group type: EXPERIMENTAL
Intervention: Head Impact (n = 65)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Match Control (n = 49)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: High-intensity Exercise (n = 35)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Heading (n = 36)
Number of subjects: 535
Study: 16000280

Group type: EXPERIMENTAL
Intervention: 123I‐PE2I bolus injection
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combined bolus and constant infusion of 123I‐PE2I
Number of subjects: 5
Study: 12833584

Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg, once daily) in combination with ramipril
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo in combination with ramipril
Number of subjects: 43
Study: 10567194

Group type: EXPERIMENTAL
Intervention: 20 mg of sustained‐release nicardipine hydrochloride twice daily
Number of subjects: 414

Group type: COMPARATOR
Intervention: 2 mg of trichlormethiazide once daily
Number of subjects: 414
Study: 8652357

Group type: EXPERIMENTAL
Intervention: Mathematics achievement test for Hong Kong Chinese children
Number of subjects: 253

Group type: COMPARATOR
Intervention: Ratings of children's competence by Canadian respondents
Number of subjects: 253

Group type: COMPARATOR
Intervention: Harter Self-Perception Profile Scale for Canadian children
Number of subjects: 253

Group type: COMPARATOR
Intervention: Harter Self-Perception Profile Scale for Hong Kong children
Number of subjects: 253
Study: 1818788

Group type: EXPERIMENTAL
Intervention: Nitrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6346558

Group type: EXPERIMENTAL
Intervention: No parenchymal lymphatic vessel invasion and no lymph node metastasis
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: No lymphatic vessel invasion but with lymph node metastasis
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Lymphatic vessel invasion and no lymph node metastasis
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Lymphatic vessel invasion with lymph node metastasis
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: No blood vessel invasion and with neither lymph node metastasis nor lymphatic vessel invasion
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Either or one, or both lymph node metastasis or lymphatic vessel invasion present
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Blood vessel invasion without lymph node invasion or lymphatic vessel invasion
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Blood vessel invasion with either one or both lymph node invasion or lymphatic vessel invasion
Number of subjects: 685
Study: 3859943

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30608622

Group type: EXPERIMENTAL
Intervention: Brochure plus standard result notification letter
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (standard notification letter alone)
Number of subjects: 105
Study: 28827051

Group type: EXPERIMENTAL
Intervention: Hydrostatic reduction with normal saline
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pneumatic reduction with air
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Hydrostatic reduction
Number of subjects: 124
Study: 27777219

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 72139

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 72139
Study: 24663014

Group type: EXPERIMENTAL
Intervention: Rifampin alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoniazid alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoniazid with nevirapine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isoniazid with efavirenz
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rifampin with nevirapine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rifampin with efavirenz
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall pharmacokinetics of rifampin and isoniazid
Number of subjects: 38
Study: 23109024

Group type: EXPERIMENTAL
Intervention: New gastric lavage protocol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic gastric lavage method
Number of subjects: 120
Study: 20956765

Group type: EXPERIMENTAL
Intervention: Carbon dioxide at body temperature
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbon dioxide at room temperature
Number of subjects: 30
Study: 18805108

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 155
Study: 16082684

Group type: EXPERIMENTAL
Intervention: Rotational angiography
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard angiography
Number of subjects: 50
Study: 12789223

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Other Antihistamines (OAH)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonteratogenic Controls (NTC)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Loratadine (first trimester)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Other Antihistamines (OAH) (first trimester)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonteratogenic Controls (NTC) (first trimester)
Number of subjects: 210
Study: 11070566

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised feeding regimen
Number of subjects: 0
Study: 9082488

Group type: EXPERIMENTAL
Intervention: Aspirin treatment for primary prevention of coronary heart disease
Number of subjects: 0
Study: 1634452

Group type: EXPERIMENTAL
Intervention: Theolan preparation (once a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theolan preparation (twice a day)
Number of subjects: 10
Study: 6499384

Group type: COMPARATOR
Intervention: Magnesium citrate alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Magnesium citrate with bisacodyl (oral or rectal)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Magnesium citrate with sodium picosulphate (Picolax)
Number of subjects: 2
Study: 30734418

Group type: EXPERIMENTAL
Intervention: Worksite-based weight reduction program
Number of subjects: 58
Study: 28893752

Group type: EXPERIMENTAL
Intervention: Olfactory prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both primes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall hand hygiene compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital-acquired infections
Number of subjects: 0
Study: 27052741

Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Number of subjects: 52

Group type: COMPARATOR
Intervention: Room temperature IV fluids (control group)
Number of subjects: 52
Study: 25237668

Group type: EXPERIMENTAL
Intervention: Computer-guided implant placement aided with templates
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional implant placement without templates
Number of subjects: 51
Study: 22424803

Group type: EXPERIMENTAL
Intervention: Contact lens-based artificial pupil designs
Number of subjects: 0
Study: 19492715

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Hybrid composite restorative material
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Indirect restoration with buildup material
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cavity depth (shallow, medium, deep)
Number of subjects: 123
Study: 17635433

Group type: EXPERIMENTAL
Intervention: Truview blade
Number of subjects: 170

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 170
Study: 15059707

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no lipid-lowering therapy)
Number of subjects: 30
Study: 12452458

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg orally
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Oxytocin (control)
Number of subjects: 1686
Study: 10791608

Group type: EXPERIMENTAL
Intervention: Emotional self-management skills course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8683286

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (intravenous and oral) for 3 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo treatment for 3 weeks
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Nimodipine treatment (intravenous and oral) for 3 weeks (compliant patients only)
Number of subjects: 123
Study: 1803712

Group type: EXPERIMENTAL
Intervention: Estrogen Receptor (ER) positive status
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Estrogen Receptor (ER) levels greater than 100 fmol/mg protein
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Progesterone Receptor (PgR) status
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Progesterone Receptor (PgR) levels
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: ER and PgR profiles
Number of subjects: 1095
Study: 6360027

Group type: EXPERIMENTAL
Intervention: Methysergide, 8 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methysergide
Number of subjects: 0
Study: 31479287

Group type: EXPERIMENTAL
Intervention: Single-task condition (cough testing only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-task condition (counting tones while undergoing cough testing)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-task condition and Dual-task condition
Number of subjects: 20
Study: 29879241

Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant (FMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0
Study: 27302362

Group type: EXPERIMENTAL
Intervention: EGCG (9 mg/kg per day) plus cognitive training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo plus cognitive training
Number of subjects: 84
Study: 26546644

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 54
Study: 23649850

Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Punctal Plugs (PP)
Number of subjects: 42
Study: 20505508

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 113

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 113
Study: 19055333

Group type: EXPERIMENTAL
Intervention: Noninvasive interactive neurostimulation (active)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham noninvasive interactive neurostimulation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (active and sham)
Number of subjects: 37
Study: 16256278

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE) as a screening tool for cognitive impairment
Number of subjects: 10791

Group type: EXPERIMENTAL
Intervention: Higher MMSE scores in an inpatient detoxification unit
Number of subjects: 10791

Group type: EXPERIMENTAL
Intervention: Cognitive function impact on follow-up in medical inpatients with unhealthy alcohol use
Number of subjects: 10791
Study: 12809958

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg QD
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg QD
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 11015339

Group type: EXPERIMENTAL
Intervention: Lowest LPL activity quartile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest LPL activity quartile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPL protein mass
Number of subjects: 0
Study: 9129860

Group type: EXPERIMENTAL
Intervention: Lovastatin monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1548825

Group type: EXPERIMENTAL
Intervention: Aztreonam 100 mg three times a day for 5 days
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 3919805

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 140